




Financial highlights

The Sawai Group has adopted International Financial Reporting Standards (IFRS) in the preparation of its consolidated financial statements from fiscal 2017.


Revenue / Core operating profit



In fiscal 2021, the Sawai Group posted record revenue for various reasons, including an increase in fiscal 2020 product sales, despite drug price revisions and limited shipments due to the suspension of supplies by other companies. Core operating profit fell because of an increase in R&D expenses in Japan and the impact of major rival generic drugs in the U.S. business.

Note: Fiscal years 2012 through 2016 show figures for revenue based on Japanese-GAAP.


Profit attributable to owners of the Company / Return on equity



In a challenging environment for both the Japan business and the U.S. business, the Group worked to secure profits by aggressively reducing raw material and other costs. In fiscal 2021, the Group posted a loss attributable to owners of the Company of ¥28,269 million as a result of impairment on intangible assets, including goodwill for the U.S. business.

Note: Fiscal years 2012 through 2016 show figures for profit attributable to owners of parent and return on equity based on Japanese-GAAP.


R&D expenses



The Sawai Group invested aggressively in research and development in order to be first to market with new products that will differentiate us from our competitors to achieve future growth. In fiscal 2021, R&D expenses rose 75.8% year on year to ¥24,413 million for several reasons, including the recording of an impairment loss of ¥2,233 million for the Japan business and ¥5,724 million for the U.S. business.

Note: Fiscal years 2012 through 2016 show figures for R&D expenses based on Japanese-GAAP.

Dividends per share / Dividend payout ratio




We aim to pay stable and continuous dividends with a target payout ratio of 30%, taking account of the balance between investment for growth and dividends, as well as comprehensively considering the consolidated financial results for each fiscal year, the dividend payout ratio, and other measures aimed at shareholder returns. In fiscal 2021, the Company provided an annual return to shareholders of ¥130 per share.

Note: As the Company implemented a two-for-one stock split of its common shares on October 1, 2013, figures for fiscal 2012 through 2013 were recalculated to reflect this split.

Non-financial highlights


Scope of data: Sawai Pharmaceutical Co., Ltd.

Number of GMP audits conducted by Sawai Pharmaceutical




Sawai Pharmaceutical has formed a dedicated audit team, which performs more than 100 GMP audits a year. The number of audits conducted each fiscal year fluctuates within a certain range as the year for the next audit is determined based on the results of the previous audit. Because of the COVID-19 pandemic, it was impossible to conduct onsite audits of manufacturing sites, particularly those overseas, but the work was supplemented through remote audits and (commissioned) third-party audits.

Sales volume / Production capacity




The Group's ability to supply a relatively large number of top quality generic drugs is backed by our industry-leading production capacity. We are also able to adjust production in accordance with supply and demand due to the high proportion of in-house manufacturing.

Number of patents held



We own a variety of patents, including a patent for reducing the bitterness of active ingredients and a patent for orally dissolving (OD) tablets that can be taken without water. Recently, there has been an increase in the number of patent applications for unique Sawai formulation technologies (SAWAI HARMOTECH) that are not linked to specific active ingredients.

Amount of reduction in healthcare costs



The Sawai Group's greatest contribution to society lies in increasing the sustainability of the health insurance system by reducing the burden of medical expenses through the supply of generic drugs. We have contributed to reducing healthcare costs by approximately ¥300.0 billion.